February 25th, 2021
Atrial fibrillation is the most common type of arrhythmia, affecting 1-3% of the population. It is a known fact that atrial fibrillation is associated with strokes, embolisms, heart failure and dementia. However, the exact mechanism between the heart rhythm and the formation of blood clots is unknown. This mechanism is the focus of The Swiss-AF-Burden study, a research program funded by the Swiss National Science Foundation.
The University Hospital in Basel has just started a cooperation with Cardiomatics – an INNOventure-backed company. The technology provided by the Krakow-based startup will enable the analysis of variability and frequency of atrial fibrillations in long – seven-day – Holter records. Cardiomatics’ innovative cloud-based technology that automates the analysis enables fast and accurate processing of large measurement data sets required for this research project.
The results of this research will enable the creation of therapies tailored to a specific patient. This is of great importance, given that the number of patients suffering from atrial fibrillation is expected to increase severalfold over the next decades, and the effects of the disease are serious – including a five-fold increase in the risk of stroke, a ten-fold increase in the risk of heart failure and a two-fold increase in mortality.